Technical Analysis for CRSP - CRISPR Therapeutics AG
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| See historical CRSP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 22 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Mar 22 | BB Squeeze + Lower Band Touch | Range Contraction | 0.00% |
| Mar 22 | BB Squeeze Started | Range Contraction | 0.00% |
| Mar 22 | Lower Bollinger Band Touch | Weakness | 0.00% |
| Mar 21 | 20 DMA Resistance | Bearish | -6.00% |
| Mar 21 | Bullish Engulfing | Bullish | -6.00% |
| Mar 20 | Hammer Candlestick | Bullish | -4.07% |
| Mar 20 | Lizard Bullish | Bullish Day Trade Setup | -4.07% |
| Mar 20 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -4.07% |
| Mar 20 | Down 3 Days in a Row | Weakness | -4.07% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-05-06
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.
Biology Immune System Genetics Serious Diseases Genetic Engineering Enzymes Genome Editing Cas9 CRISPR
Biology Immune System Genetics Serious Diseases Genetic Engineering Enzymes Genome Editing Cas9 CRISPR
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more CRSP news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 73.9 |
| 52 Week Low | 22.22 |
| Average Volume | 803,363 |
| 200-Day Moving Average | 42.7164 |
| 50-Day Moving Average | 34.8426 |
| 20-Day Moving Average | 38.218 |
| 10-Day Moving Average | 38.074 |
| Average True Range | 2.1275 |
| ADX | 20.41 |
| +DI | 20.8705 |
| -DI | 22.7286 |
| Chandelier Exit (Long, 3 ATRs ) | 35.6475 |
| Chandelier Exit (Short, 3 ATRs ) | 37.1325 |
| Upper Bollinger Band | 41.1714 |
| Lower Bollinger Band | 35.2646 |
| Percent B (%b) | 0.06 |
| BandWidth | 15.455545 |
| MACD Line | 0.797 |
| MACD Signal Line | 1.2675 |
| MACD Histogram | -0.4705 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.44 Billion |
| Num Shares | 40.6 Million |
| EPS | -1.41 |
| Price-to-Earnings (P/E) Ratio | -25.24 |
| Price-to-Sales | 73.74 |
| Price-to-Book | 3.74 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 39.82 | ||||
| Resistance 3 (R3) | 40.15 | 39.08 | 39.12 | ||
| Resistance 2 (R2) | 39.08 | 38.00 | 38.91 | 38.88 | |
| Resistance 1 (R1) | 37.33 | 37.33 | 36.80 | 37.00 | 38.64 |
| Pivot Point | 36.26 | 36.26 | 35.99 | 36.09 | 36.26 |
| Support 1 (S1) | 34.51 | 35.18 | 33.98 | 34.18 | 32.54 |
| Support 2 (S2) | 33.44 | 34.51 | 33.27 | 32.30 | |
| Support 3 (S3) | 31.69 | 33.44 | 32.07 | ||
| Support 4 (S4) | 31.36 |
